Dynavax Technologies Corporation (DVAX): Price and Financial Metrics

Dynavax Technologies Corporation (DVAX): $12.43

0.75 (+6.42%)

POWR Rating

Component Grades













Add DVAX to Watchlist
Sign Up

Industry: Biotech



in industry


  • DVAX scores best on the Value dimension, with a Value rank ahead of 97.23% of US stocks.
  • The strongest trend for DVAX is in Stability, which has been heading up over the past 179 days.
  • DVAX ranks lowest in Stability; there it ranks in the 2nd percentile.

DVAX Stock Summary

  • The price/operating cash flow metric for Dynavax Technologies Corp is higher than only 13.52% of stocks in our set with a positive cash flow.
  • Over the past twelve months, DVAX has reported earnings growth of -257.89%, putting it ahead of merely 7.61% of US stocks in our set.
  • As for revenue growth, note that DVAX's revenue has grown 844% over the past 12 months; that beats the revenue growth of 98.82% of US companies in our set.
  • Stocks that are quantitatively similar to DVAX, based on their financial statements, market capitalization, and price volatility, are FLGT, SGH, CVLT, MIME, and YELP.
  • DVAX's SEC filings can be seen here. And to visit Dynavax Technologies Corp's official web site, go to www.dynavax.com.

DVAX Valuation Summary

  • In comparison to the median Healthcare stock, DVAX's price/sales ratio is 16.3% higher, now standing at 13.2.
  • DVAX's price/sales ratio has moved down 256.2 over the prior 213 months.
  • Over the past 213 months, DVAX's price/earnings ratio has gone down 379.3.

Below are key valuation metrics over time for DVAX.

Stock Date P/S P/B P/E EV/EBIT
DVAX 2021-08-31 13.2 26.8 -391.7 201.1
DVAX 2021-08-30 12.3 24.9 -364.1 187.7
DVAX 2021-08-27 11.5 23.3 -340.3 176.1
DVAX 2021-08-26 11.9 24.2 -353.2 182.4
DVAX 2021-08-25 11.0 22.4 -326.9 169.5
DVAX 2021-08-24 10.3 20.8 -304.5 158.7

DVAX Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 185.62%.
  • Its 3 year price growth rate is now at -48.97%.
  • The 2 year net income to common stockholders growth rate now stands at -18.35%.
Over the past 15 months, DVAX's revenue has gone up $401,871,000.

The table below shows DVAX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 439.442 335.528 72.144
2021-09-30 263.922 199.288 -38.533
2021-06-30 169.066 105.256 -5.702
2021-03-31 118.967 -27.353 -61.754
2020-12-31 46.551 -92.251 -75.24
2020-09-30 37.571 -99.52 -96.529

DVAX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVAX has a Quality Grade of B, ranking ahead of 88.86% of graded US stocks.
  • DVAX's asset turnover comes in at 0.367 -- ranking 129th of 681 Pharmaceutical Products stocks.
  • LJPC, ABT, and CVM are the stocks whose asset turnover ratios are most correlated with DVAX.

The table below shows DVAX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.367 0.719 0.023
2021-03-31 0.312 0.715 -0.092
2020-12-31 0.144 0.701 -0.128
2020-09-30 0.123 0.612 -0.182
2020-06-30 0.119 0.519 -0.278
2020-03-31 0.146 0.505 -0.263

DVAX Price Target

For more insight on analysts targets of DVAX, see our DVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.50 Average Broker Recommendation 1.38 (Strong Buy)

DVAX Stock Price Chart Interactive Chart >

Price chart for DVAX

DVAX Price/Volume Stats

Current price $12.43 52-week high $21.39
Prev. close $11.68 52-week low $7.26
Day low $11.57 Volume 3,016,300
Day high $12.46 Avg. volume 2,363,813
50-day MA $10.26 Dividend yield N/A
200-day MA $13.80 Market Cap 1.57B

Dynavax Technologies Corporation (DVAX) Company Bio

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, using TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company was founded in 1996 and is based in Berkeley, California.

DVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

DVAX Latest Social Stream

Loading social stream, please wait...

View Full DVAX Social Stream

Latest DVAX News From Around the Web

Below are the latest news stories about Dynavax Technologies Corp that investors may wish to consider to help them evaluate DVAX as an investment opportunity.

Dynavax Q4 2021 Earnings Preview

Dynavax (NASDAQ:DVAX) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is $0.60 and the consensus Revenue Estimate is $208.87M (+968.4% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen...

Seeking Alpha | February 27, 2022

Dynavax Technologies Stock Sees Relative Strength Rating Rise To 85

Dynavax Technologies saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 67 to 85. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Decades of market research reveals that the market's biggest winners often have an 80 or higher RS Rating as they launch their biggest price moves.

Yahoo | February 25, 2022

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

Yahoo | February 24, 2022

Clover Selected for Inclusion on the Hang Seng Composite Index

CHENGDU, China, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022. Hang Seng Composite IndexHang Seng Small Cap (Investable) IndexHang Seng Healthcare IndexHang Seng Hong Kong-Listed Biotech IndexHang Seng Stock Con

Yahoo | February 24, 2022

Dynavax to Present at the Cowen 42nd Annual Health Care Conference

EMERYVILLE, Calif. , Feb. 23, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will

Investors Dynavax | February 23, 2022

Read More 'DVAX' Stories Here

DVAX Price Returns

1-mo 40.77%
3-mo 1.39%
6-mo -23.03%
1-year 51.59%
3-year 150.10%
5-year 121.96%
YTD -11.66%
2021 216.18%
2020 -22.20%
2019 -37.49%
2018 -51.07%
2017 373.42%

Continue Researching DVAX

Want to see what other sources are saying about Dynavax Technologies Corp's financials and stock price? Try the links below:

Dynavax Technologies Corp (DVAX) Stock Price | Nasdaq
Dynavax Technologies Corp (DVAX) Stock Quote, History and News - Yahoo Finance
Dynavax Technologies Corp (DVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7448 seconds.